SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has expanded its epilepsy testing menu, now offering an extensive panel with ...
Invitae boosted its genetic testing menu with a new test for the diagnosis of spinal muscular atrophy, the second-leading genetic disease in infants. The test provides “significant improvements” over ...
Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the launch of its new patient pay price for its full menu of genetic tests at $475 per indication. This new price ...
San Francisco-based genetic testing company Invitae has rolled out a one-price-fits-all payment model for its range of tests, charging a set $475 for any test for patients who don’t go through their ...
A novel DNA test system that assesses a person's genetic predisposition for certain cancers —the first of its kind granted marketing authorization by the US Food and Drug Administration (FDA) — may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results